Karen Knudsen: We announce a first-in-field program to support translational research grants and early-stage equity investments in emerging oncology start-ups

Karen Knudsen shared a post on LinkedIn:

Making sure that good ideas don’t end on the laboratory floor is a major endeavor of American Cancer Society. Toward that end, we enthusiastically announce a first-in-field program made possible by Lyda Hill Philanthropies to support translational research grants and early-stage equity investments in emerging oncology start-ups.

For details click here.
Source: Karen Knudsen/LinkedIn

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.